In the amended agreement, Humacyte obtained exclusive rights to distribute Symvess outside the U.S., while Fresenius Medical Care retains U.S. distribution rights under existing terms. Fresenius will earn low-single-digit royalties on Humacyte’s net ex-U.S. Symvess sales. The modification restructures the global rights distribution without affecting U.S. vascular trauma product availability.

Humacyte plans to leverage exclusive ex-U.S. rights to advance its commercial initiatives in key markets including Saudi Arabia and Israel for vascular injury repair and other indications. The realignment enables targeted discussions with prospective corporate partners for specific international and indication-based licensing or co-development agreements.

With global rights consolidated, Humacyte is positioned to negotiate new partnerships and optimize its supply chain for Symvess. The low-single-digit royalty structure offers cost predictability, supporting scalable international launches. Maintaining U.S. terms unchanged preserves the company’s focus on domestic distribution while unlocking international revenue streams.